CrossBridge Bio
About CrossBridge Bio
CrossBridge Bio is a biotechnology company focused on advancing antibody-drug conjugate (ADC) therapeutics, developing stable dual-linker payload technology and site-specific conjugation methods. The company emphasizes improving ADC stability, precise payload release, and dual-payload combinations to enhance cancer treatment. Based in Houston, Texas, with activities centered on oncology therapeutics and translational research, it aims to bring first-in-class and best-in-class ADC solutions to patients.
Recent News
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
Eli Lilly Buys Engage Bio for $202M, Adding Non‑Viral DNA Delivery Platform
Eli Lilly to Acquire Ajax Therapeutics for ~$2.3B
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
Lilly Targets Kidney Disease with Ascidian’s RNA Exon Editors for up to $1.9B
Top Biotech Deals in April 2026
Eli Lilly and Company $LLY Shares Acquired by Freestone Capital Holdings LLC